Compare SRI & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRI | MDXH |
|---|---|---|
| Founded | 1965 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.7M | 183.4M |
| IPO Year | 1997 | 2021 |
| Metric | SRI | MDXH |
|---|---|---|
| Price | $8.00 | $3.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $16.00 | $7.67 |
| AVG Volume (30 Days) | ★ 193.1K | 90.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $824,444,000.00 | N/A |
| Revenue This Year | N/A | $23.34 |
| Revenue Next Year | $6.43 | $22.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.46 | N/A |
| 52 Week Low | $3.54 | $1.35 |
| 52 Week High | $9.71 | $5.33 |
| Indicator | SRI | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 52.38 | 49.82 |
| Support Level | $6.61 | $3.05 |
| Resistance Level | $8.79 | $3.78 |
| Average True Range (ATR) | 0.54 | 0.18 |
| MACD | -0.12 | 0.00 |
| Stochastic Oscillator | 20.52 | 42.50 |
Stoneridge Inc is a manufacturer of electrical and electronic components used in automotive vehicles. The company produces instrumentation systems, vehicle management electronics, application-specific switches and actuators, sensors, security alarms, and vehicle tracking devices and monitoring services for commercial, automotive, off-highway, and agricultural vehicle markets. The company has three reportable segments: Control Devices, Electronics, and Stoneridge Brazil. It generates the majority of its revenue from the Electronics segment that produces driver information systems, camera-based vision systems, connectivity, and compliance products, and electronic control units. Its geographic segments include America, South America, Europe and Other.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.